Open Journal Systems

Top ten most accessed AMOR articles in 2015/2016

Editorial Office ()

Abstract


In 2015/2016, Advances in Modern Oncology Research published a total of 67 articles over eight issues in two separate volumes. These published articles, consisting of editorials, reviews, case reports, and original research, have collectively accumulated 26,320 views as of December 2016. A total of 54 authors and 160 peer-reviewers from across the globe contributed to the journal in its first full year of publication. The journal’s top ten most accessed articles are:

1. Indoles as anticancer agents (Vol. 1 Issue 1) 
 
2. Pharmacometrics and systems pharmacology of immune checkpoint inhibitor nivolumab in cancer translational medicine (Vol. 2 Issue 1) 
 
3. Hepatocellular carcinoma (HCC); aetiological considerations (Vol. 1 Issue 1) 
 
4. Oligoadenylate synthetase 1 (OAS1) expression in human breast and prostate cancer cases, and its regulation by sex steroid hormones (Vol. 2 Issue 2) 
 
5. Antiproliferative effects of cembranoid derivatives obtained from Red Sea soft coral Sarcophyton glaucum on human colorectal cancer cell lines (Vol. 1 Issue 1) 
 
6. Paraneoplastic pemphigus: A trait d’union between dermatology and oncology (Vol. 1 Issue 2) 
 
7. Cancer cell metastasis; perspectives from the focal adhesion (Vol. 1 Issue 1) 
 
8. Threshold-based parametric analysis of diffusion-weighted magnetic resonance imaging at 3.0 Tesla to identify men with prostate cancer (Vol. 1 Issue 2) 
 
9. Economic burden of patients with inoperable advanced breast cancer receiving early or late capecitabine or trastuzumab as second-line treatment: A population-based study (Vol. 1 Issue 2) 
 
10. Non-coding RNAs: New therapeutic targets and opportunities for hepatocellular carcinoma (Vol. 2 Issue 1)


Full Text:

PDF

DOI: http://dx.doi.org/10.30564/amor.v2i6.87

Refbacks

  • There are currently no refbacks.


Copyright (c) 2018 Editorial Office

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.